The Endocannabinoid System and the Control of Glucose Homeostasis
Open Access
- 17 April 2008
- journal article
- review article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 20 (s1), 147-151
- https://doi.org/10.1111/j.1365-2826.2008.01692.x
Abstract
Blockade of the CB(1) receptor is one of the promising strategies for the treatment of obesity. The first selective CB(1) receptor antagonist, rimonabant, which has already successfully completed phase III clinical trials, led to sustained weight loss and a reduction in waist circumference. Patients treated with rimonabant also demonstrated statistically significant improvement in high-density lipoprotein cholesterol levels, triglyceride levels and insulin resistance, as well as a reduced overall prevalence of metabolic syndrome. Currently, one of the most discussed aspects of endocannabinoid system function is to what extent the endocannabinoid system might affect metabolism independently of its control over body weight and food intake. Specifically, a food-intake- and body-weight-independent role in the regulation of glucose homeostasis and insulin sensitivity could have major impact on the potential of drug candidates targeting the endocannabinoid system for the prevention and treatment of metabolic syndrome. This review summarises the effects of the endocannabinoid system on glucose homeostasis and insulin sensitivityKeywords
This publication has 38 references indexed in Scilit:
- Visceral Adipocytes and the Metabolic SyndromePublished by Oxford University Press (OUP) ,2008
- Visceral Adipocytes and the Metabolic SyndromeNutrition Reviews, 2007
- Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal ObesityDiabetes, 2006
- Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeJCI Insight, 2006
- The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3T3 F442A PreadipocytesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2005
- The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balanceThe FASEB Journal, 2005
- Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob miceInternational Journal of Obesity, 2004
- CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivityInternational Journal of Obesity, 2004
- Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and HyperinsulinemiaJournal of Clinical Endocrinology & Metabolism, 2001
- AdipoQ Is a Novel Adipose-specific Gene Dysregulated in ObesityJournal of Biological Chemistry, 1996